Edaravone treatment of 56 cases of acute cerebral infarction
Abstract: Objective: To investigate pulled by Diego Bong injection in treating acute cerebral infarction and security. Methods: 115 cases of hospitalized patients with acute cerebral infarction were randomly divided into two groups, treatment group 56 cases, 59 cases were New Zealand, treatment treatment of cerebral infarction group was given based program on the use of edaravone injection 30mg, respectively, before treatment, after treatment, 7,14,21 d assess their degree of neurological deficit (ESS) and activities of daily living (ADL). Results: The total effective rate was significantly higher, the difference was statistically significant (P <0.05. edaravone Rule 14d neurological improvement than the control group (P <0.05, to 21d is better than when the same the control group (P <0.05), 21d neurological deficit after treatment than before treatment improved (P <0.05.ADL improvement in the treatment of 14,21 d than the control group (P <0.05. edaravone group 3 cases rash, not stopping to relieve itself, three cases of subcutaneous petechiae, withdrawal symptoms, one case of liver dysfunction, returned to normal after discontinuation. no intracranial hemorrhage and gastrointestinal bleeding. Conclusions: By Dara Upon treatment of acute cerebral infarction significantly improve neurological function and safety.
Keywords: acute infarction, edaravone
Acute cerebral infarction is a common disease, there is a high incidence of complications, morbidity, high mortality characteristics, studies suggest that associated with severe atherosclerosis, thrombosis extension, collateral circulation vascular occlusion, blood histological changes, blood hypercoagulable state and mental factors, of which free radical damage is the result of brain edema formation and apoptosis main reason [1]. Edaravone is a free radical scavenger, can clear the brain missing When blood free radicals generated by neuronal membrane of nerve cells play a protective role in our hospital in January 2008 ~ December 2010 edaravone 56 patients with acute cerebral infarction, and achieved good effect, the results reported as follows.
1 Materials and Methods 1.1 Clinical data within 24 h of onset of acute cerebral infarction patients with 115 cases, are in line with the Fourth National Conference on Cerebrovascular Disease << adopted various cerebrovascular disease diagnostic criteria >> diagnostic criteria of acute cerebral infarction diagnosis [ 2], and by CT or MRI scan confirmed, and in accordance with the following conditions: ① no previous history of head trauma and cerebral vascular accident history or other encephalitis medical history, medical history and other intracranial mass. ② exclude cerebral hemorrhage, ③ except TIA and cerebral embolism, ④ rule out bleeding disorders or bleeding tendency, including gastrointestinal ulcers or blood system diseases, the presence of infectious diseases, ⑤ exclude severe heart, lung, liver, kidney failure situation; ⑥ European Stroke Score (ESS) score <80 points, Glasgow (Glasgow) coma score (GCS)> 6 points would be 115 acute cerebral infarction were randomly divided into treatment and control groups: (a treatment group, 56 cases: male: female was 1.07:1 ( 29/27, mean age (56.4 + -13.73) years of age. infarction parts: basal ganglia infarction in 10 cases, watershed infarction in 12 cases, the basilar artery syndrome (brain stem, occipital lobe, thalamus multi-infarct in 11 cases, cerebellar infarction eight cases, the beginning part of the internal carotid artery infarction 12 cases, the other three cases (two control group 59 cases: male: female was 1.11:1 (31/28, mean age (58.5 + -14.92) years of age. infarction parts: basal ganglia infarction in nine cases, watershed infarction in 16 cases, the basilar artery syndrome (brain stem, occipital lobe, thalamus multi-infarct 7 cases, 11 cases of cerebellar infarction, the beginning part of the internal carotid artery infarction 14 cases, the other two cases. two set of data on gender, age, weight, brain imaging before treatment, severity, past history (hypertension, diabetes, hyperlipidemia, heart disease, etc.) manifestations, complications, etc. There was no significant difference (P> 0.05 , comparable.
1.2 Treatment? Groups were conventional oxygen, cerebral edema, control of blood pressure and blood sugar, lowering blood pressure, protect the stomach, prevent complications, maintain water and electrolyte balance, plus co-infection with antibiotics and other symptomatic treatment. Ban this period thrombolytic, fibrinolytic and other anticoagulant drugs, leukocyte adhesion inhibitors, oxygen radical scavengers and other neuroprotective agents such as vitamin E, vitamin C, citicoline, piracetam, aescin, etc. . (a control group: 0.4g Xuesetong needle plus 0.9% saline 100ml intravenous infusion, day 1, once every 21d, aspirin tablets 100mg / d, low molecular weight heparin 5000IU, abdominal subcutaneous, l2h once every 7d. (2 treatment groups: control group, based on the addition of edaravone injection 30m g 100ml normal saline infusion, 30min completed within the drop, 2 times a day, once every 21d. Patients in both groups prohibit the use of thrombolytic, fibrinolytic and other anticoagulant drugs, oxygen free radical scavengers and other neuroprotective agents.
1.3 OUTCOME MEASURES fasting venous blood collected two groups of patients, all laboratory tests are in strict accordance with the instrument and the kit instructions for testing requirements. ① blood testing blood, fasting blood glucose, blood lipids, liver and kidney function, blood clotting . ② neurological deficit scores using the European Stroke Scale score (the European stroke scale, ESS), activities of daily living (ADL), using the Barthel index scale (modified barther index, MBI) score, respectively, before treatment, 7,14,21 d after treatment were scored, ③ routine monitoring of body temperature, blood pressure, level of consciousness, limb function, to record adverse reactions. ④ routine head CT, transcranial Doppler and neck vascular ultrasound examination, laboratory examination before treatment and after treatment of each detection 21d 1.
1.4 Clinical criteria [2]? ① basic cure: functional impairment score decreased from 91% to 100%, the degree of disability 0, ② markedly: functional impairment score decreased by 46% to 90% degree of disability from 1 to 3, ③ Progress: functional impairment score decreased by 18% to 45% degree of disability 4. ④ invalid: function defect score increased within 17%, ⑤ worse: functional impairment score increased by 18% or more, or death. basically cured, effective, progressive are assessment be valid, no change or worsening as invalid.
1.5 statistical methods between the two groups count data using χ2 test, measurement data using t test, taking a = 0.05 for the test level. Statistical analysis by the SPSS 13.0 software.
..com
2 Results
2.1 Comparison of two groups: the treatment group was significantly higher, the difference was statistically significant (P <0.05. (See Table 1 Table 1 Comparison of two groups .com/Newspic/2013122/852418965.jpg” border=0>
本文来源：https://www.2haoxitong.net/k/doc/ad7522d803d276a20029bd64783e0912a2167cce.html
文档为doc格式